Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer

NCT02116894 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: PF-03446962
DRUG: Regorafenib

Sponsor

Duke University

Collaborators

[object Object]